

WILENTZ

—ATTORNEYS AT LAW—

WILENTZ, GOLDMAN & SPITZER, P.A.

Ozempic Litigation

Results achieved in prior matters are not meant to be a guarantee of success as the facts and legal circumstances vary from matter to matter.

The meteoric rise in Ozempic use has resulted in serious adverse health consequences. Ozempic, originally prescribed as a medication to treat type-2 diabetes, exploded in popularity after evidence showed it may support weight loss. But now, after only a few years on the market, thousands of users have reported that their use of Ozempic caused gastrointestinal issues such as gastroparesis and other severe side effects. Through June 30, 2023, over 8,500 users had [reported gastrointestinal problems to the FDA](#).

Wegovy, another semaglutide-based drug approved for weight loss, has also been [associated with similar health risks](#).

Novo Nordisk, a leading global healthcare company founded in 1923 and U.S. headquartered in New Jersey, manufactures both drugs. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. On December 5, 2017, the FDA approved Ozempic for improving glycemic control in adults with type-2 diabetes. Since then, it has become one of the top 100 prescribed medications in the U.S., with over 8 million prescriptions. On June 4, 2021, the [FDA approved Wegovy for weight loss](#).

In response to adverse effects, hundreds of lawsuits have now been filed against Novo Nordisk. The lawsuits allege that the medication was defectively designed and that the manufacturer failed to warn the users of the associated hazards. In Pennsylvania, these cases are consolidated in a Multi District Litigation (MDL). An MDL is a consolidated judicial proceeding designed to streamline [lawsuits involving common factual questions](#). As of August 2024, hundreds have already filed suit, and it is anticipated that thousands more will follow.

These allegations are not unfounded. [Recent studies](#) have found a causal link between gastrointestinal problems with Ozempic/Wegovy usage. While gastrointestinal problems are most prevalent, recent studies have also linked the use of these products to additional harms such as gallbladder disease.

Wilentz, Goldman & Spitzer, P.A. is currently investigating lawsuits on behalf of Ozempic and Wegovy users experiencing the following:

- abdominal distension (swelling or bloating of the abdomen)
- gastroenteritis (inflammation of the stomach and intestines causing nausea, vomiting, diarrhea, and stomach cramps.)
- gastroparesis (delayed stomach emptying due to weakened stomach muscles or nerve issues, leading to nausea, vomiting, early satiety, and bloating)
- gallbladder disease (including gallstones and cholecystitis)

If you are experiencing problems or have concerns about your medication, consult your doctor before starting or discontinuing any treatment.

To speak with an attorney about your legal options, call: 908-641-2991

Are you an attorney with an Ozempic case to file in New Jersey? [Click here](#).

To speak with an attorney about your legal options, please call: 908-641-2991.